Endurant Capital Management LP Immunic, Inc. Transaction History

Endurant Capital Management LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$3.13 - $12.25 $312,924 - $1.22 Million	-99,976 Reduced 76.57%	30,591 $106,000
Q1 2022 May 16, 2022	SELL	$9.54 - $14.26 $514,931 - $769,697	-53,976 Reduced 29.25%	130,567 $1.48 Million
Q4 2021 Feb 14, 2022	SELL	$7.34 - $10.25 $6,642 - $9,276	-905 Reduced 0.49%	184,543 $1.77 Million
Q3 2021 Nov 15, 2021	BUY	$8.05 - $13.29 $66,815 - $110,307	8,300 Added 4.69%	185,448 $1.64 Million
Q2 2021 Aug 16, 2021	BUY	$11.76 - $16.85 $533,339 - $764,181	45,352 Added 34.41%	177,148 $2.17 Million
Q1 2021 May 17, 2021	SELL	$14.21 - $25.3 $96,869 - $172,470	-6,817 Reduced 4.92%	131,796 $2.1 Million
Q4 2020 Feb 16, 2021	BUY	$14.8 - $20.37 $409,989 - $564,289	27,702 Added 24.98%	138,613 $2.12 Million
Q3 2020 Nov 16, 2020	BUY	$11.74 - $22.0 $1.3 Million - $2.44 Million	110,911 New	110,911 $2.06 Million

56.3M

100

350K

Ticker IMUX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,565,000
Market Cap $30.3M
Description
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...

Get notified when there are updates to the investment portfolio of Endurant Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Endurant Capital Management LP with notifications on news.